Candel Therapeutics appoints Martine Zimmermann to board of directors

Candel Therapeutics appoints Martine Zimmermann to board of directors
Candel taps Zimmermann for board

Candel Therapeutics has announced the appointment of Martine Zimmermann to its board of directors. Zimmermann brings more than 30 years of experience in regulatory affairs and quality management across multiple stages of drug development.

Her expertise is expected to enhance Candel Therapeutics leadership as the company advances its pipeline through various regulatory and commercial phases.

Candel Therapeutics recently shared new immune response data for aglatimagene in localized prostate cancer, reinforcing phase 3 trial outcomes in a previous update. The company is also set to present new data on aglatimagene besadenovec and linoserpaturev at the SITC annual meeting in November, according to a recent announcement. These developments mark ongoing efforts to advance its pipeline through clinical stages.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.